GU Cancers 2023 | Criteria for treatment selection for patients with CRPC

Silke Gillessen, MD, Oncological Institute of Southern Switzerland, Bellinzona, Switzerland, discusses factors to consider when choosing a treatment plan for patients with prostate cancer, including the potential use of precision medicine and molecular profiling as well as the patient’s ability to tolerate harsh adverse effects of chemotherapy. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.